Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Grants Merck & Co. Priority Review for Cervical Cancer Vaccine

February 8, 2006

The Food and Drug Administration has granted Whitehouse Station, N.J.-based Merck & Co. priority review for the company's cervical cancer vaccine. An FDA decision on the vaccine, which would be sold under the brand name Gardasil, is expected by June 8. Gardasil is designed to protect against four strains of human papillomavirus that are linked to cervical cancer in women and to genital warts in men and women. If approved, Gardasil would be the first cervical cancer vaccine on the U.S. market. FDA grants priority review, which cuts about four months off the usual 10-month review period, for treatments it considers advancements over current therapies. Merck is also seeking approval in the European Union and in countries such as Brazil and Mexico.

Back to other news for February 8, 2006

Adapted from:
Wall Street Journal
02.08.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement